Drugs /

v941

Back to Drugs List

Overview

NCI Definition [1]:
A lipid nanoparticle (LNP)-formulated mRNA-based cancer vaccine that targets four of the most commonly occurring KRAS mutations (G12D, G12V, G13D, and G12C), with potential immunostimulatory and antineoplastic activities. Upon vaccination, the mRNA-derived KRAS-targeted vaccine V941 (mRNA-5671) is taken up and translated by antigen presenting cells (APCs). Following translation, the epitopes are presented via major histocompatibility complex (MHC) molecules on the surface of the APCs. This leads to an induction of both cytotoxic T-lymphocyte (CTL)- and memory T-cell-dependent immune responses that specifically target and destroy tumor cells harboring these specific KRAS mutations. KRAS, a tumor-associated antigen (TAA), is mutated in a variety of tumor cell types. It plays a key role in tumor cell proliferation and survival and is associated with tumor initiation, metastasis and poor prognosis.

Clinical Trials

View Clinical Trials for v941

V941 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating v941, 1 is phase 1 (1 open).

Deficient DNA Mismatch Repair (dMMR), HLA-A*11:01 Positive, and HLA-C*08:02 Positive are the most frequent biomarker inclusion criteria for v941 clinical trials.

Malignant colorectal neoplasm, non-small cell lung carcinoma, and pancreatic adenocarcinoma are the most common diseases being investigated in v941 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating V941
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating v941 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
v 941, mrna-derived kras-targeted vaccine v941, mrna 5671, mrna-5671, mrna-5671 vaccine
Drug Target(s) [2]:
KRAS
NCIT ID [1]:
C162186

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.